Our work on a novel gene expression-based prognostic model of post-autologous stem-cell transplanted (ASCT) failure-free survival in cHL has been published in Journal of Clinical Oncology! This work, which was co-led by Fong Chun Chan and Anja Mottok, has led to the development of a validated clinically applicable prognostic assay that at the time of first relapse identifies patients with unfavourable post-ASCT outcomes.